CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER (cefepime hydrochloride)
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Skin and Skin Structure Infections; Intra-Abdominal Infections.
How CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Works
Cefepime is a fourth-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It binds to one or more of the penicillin-binding proteins (PBPs), which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. This disruption leads to bacterial cell wall instability and subsequent osmotic lysis. It possesses a broad spectrum of activity against various Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*.
Details
- Status
- Prescription
- First Approved
- 2010-05-06
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Approval History
What CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Treats
5 indicationsCEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is approved for 5 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Pneumonia
- Febrile Neutropenia
- Urinary Tract Infection
- Skin and Skin Structure Infections
- Intra-Abdominal Infections
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT01484015 | IRB00015247 NCI-2011-02422, CCCWFU 02110 | Ph 1 | completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER FDA Label Details
Indications & Usage
FDA Label (PDF)CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Skin and Skin Structure Infections; Intra-Abdominal Infections.
Track CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.